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dialysis modality that best serves the 
patient ’ s lifestyle, expectations, and emo-
tional health can ease this transition. Th e 
only way to defi nitively determine whether 
diff erences in medical outcomes are attrib-
utable to a given dialysis modality is to 
undertake a randomized controlled trial. 
Th e launching of such a trial is being con-
sidered in China. Even if such a clinical 
trial is successful, it is highly unlikely that 
it will be adequately powered to inform 
decision making in subgroups of patients 
such as those with diabetes or congestive 
heart failure. In the absence of randomized 
controlled clinical trials, do observational 
studies provide enough certitude that they 
should inform a medical decision that has 
profound eff ects on virtually every aspect 
of a patient ’ s life? Th e issue of residual con-
founding is real and potentially substantial 
in a disease state as complex as end-stage 
renal disease. Over the past decades, ran-
domized controlled trials have upended 
the conventional wisdom of trying to 
achieve higher urea clearances or higher 
hemoglobin targets. 9,10 Th e magnitude of 
uncertainty with observational studies is 
too high to deny any patient with end-
stage renal disease, including those with 
congestive heart failure, a choice in the 
selection of their dialysis modality. Instead, 
such studies should be used to identify 
gaps in clinical care that should be targeted 
for improvement. 
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 Detrimental effects of dual 
ACEI – ARB therapy: is the 
(pro)renin receptor the 
culprit ? 
 Fernando  Elijovich 1 and  Cheryl L.  Laffer 1 
 Chan  et al. report increased mortality with angiotensin-converting 
enzyme inhibitors and angiotensin type 1 receptor blockers in 
hemodialysis patients, supporting emerging evidence that such dual 
therapy may be detrimental. We speculate that effects of reactive renin 
and prorenin release on the (pro)renin receptor may explain this 
apparent paradox, either through membrane-bound generation of 
angiotensin II or via stimulation of signal transduction pathways. 
Potential benefits of direct renin inhibitors and yet-to-be-developed 
(pro)renin receptor blockers are discussed. 
 Kidney International (2011)  80, 911 – 914;  doi: 10.1038/ki.2011.264 
 Th e renin – angiotensin system (RAS) plays 
a role in the target organ damage of cardio-
renal disorders, above and beyond its blood 
pressure effects. This may be due to the 
experimentally proven proinfl ammatory, 
pro-oxidative, and growth-promoting 
actions of angiotensin II (Ang II). Hence, 
clinical trials have shown that addition of 
angiotensin-converting enzyme inhibitors 
(ACEIs) or angiotensin type 1 (AT 1 ) recep-
tor blockers (ARBs) to baseline therapy 
reduces cardiovascular morbidity and 
mortality in patients with heart failure, 
hypertension, and atherosclerotic heart dis-
ease and slows progression of renal dysfunc-
tion in those with diabetic or nondiabetic 
glomerulopathies. 
 Th e kinetics of angiotensin-converting 
enzyme (ACE) inhibition by ACEIs, the 
noncompetitive albeit surmountable block-
ade of AT 1 by ARBs, and the feedback 
release of renin in response to these agents 
predict that full blockade of the RAS cannot 
be achieved when used individually. Test-
ing the speculation that more profound 
blockade of the RAS by the combination of 
ACEIs with ARBs would confer additional 
morbidity benefi ts has given controversial 
results. Hospitalization rates were reduced 
in patients with heart failure in the CHARM 
Added and Val-HeFT trials, but harm 
signals were detected in post-myocardial 
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infarction subjects (VALIANT trial) and in 
those with diabetes or high risk for cardio-
vascular disease (ONTARGET). Lack of 
additional cardiovascular benefi t with the 
combination (compared with its individual 
components) was associated with increased 
toxicity, mostly hypotension, hyperkalemia, 
and renal dysfunction. 
 Chan  et al. 1 now present two combined 
retrospective studies on the eff ects of RAS 
blockade in a very large cohort of chronic 
hemodialysis patients. Th e information is 
important not only owing to its novelty 
and the size of the cohort but also because 
cardiovascular morbidity and mortality in 
this population are greater than expected 
from their coexistent traditional cardio-
vascular risk factors. Moreover, in contrast 
to the unquestionable benefi t from RAS 
blockade in earlier stages of renal disease, 
the eff ects of such intervention in the dial-
ysis population are more controversial. 
 In their fi rst study (up to 2 years of fol-
low-up), the authors compare mortality 
rates in subjects given ACEIs versus ARBs 
at least 60 days aft er initiation of hemo-
dialysis (to prevent carryover eff ects from 
ongoing therapy). A marginal mortality 
advantage of ARBs was not confi rmed in 
an adjusted analysis. In the second study 
(also up to 2 years of follow-up), mortality 
was compared among subjects to whom an 
additional antihypertensive drug was 
given, resulting in three groups: ACEIs plus 
ARBs, ACEIs plus other agents, and ARBs 
plus other agents. Adjusted cardiovascular 
death was highest in the ACEI  +  ARB 
group, adding another piece of evidence to 
the harm signal detected in randomized 
clinical trials. 
 Both studies suff er from the drawbacks 
inherent in a retrospective design. Major 
confounders included (1) the lack of 
ascertainment of use of RAS blockers 
before dialysis; (2) overlap of the two stud-
ies (i.e., patients may have received 
another antihypertensive drug before 
the end of the fi rst 2-year study but their 
data contributed nonetheless to the com-
parison between ACEI and ARB mono-
therapies; however, they also became 
participants in the second study from the 
date of onset of the second treatment); (3) 
major diff erences in the clinical character-
istics and risk profi les of the patients given 
ACEIs versus ARBs in the fi rst study, and 
of those given ACEIs  +  ARBs versus the 
other treatments in the second; and (4) 
the unbalanced number of participants in 
the second study (only 7.5 % of the sub-
jects received ACEIs  +  ARBs). Th e authors 
must be congratulated for dealing with 
these confounders with painstaking 
statistical care, using propensity scores 
and covariates and reproducing results in 
propensity-score-matched subgroups. 
Nonetheless, they acknowledge that sta-
tistical controlling cannot fully overcome 
the potential effects of unknown con-
founders on the results, and that their 
retrospective studies should be considered 
as hypothesis generating, not altering the 
practice of medicine but stimulating 
prospective research. 
 Harmful effects of dual ACEI – ARB 
blockade are counterintuitive, not only 
because of the expectation that more pro-
found blockade of the RAS would pro-
duce more benefi t, but also because the 
ensuing reactive rise in renin secretion 
should contribute to activation of protec-
tive mechanisms. For example, increased 
circulating Ang I should be converted to 
Ang 1 – 7 by ACE2 and stimulate the  mas 
receptor, and conversion of some of this 
Ang I to Ang II despite ACEIs (via ACE 
itself or non-ACE pathways) should 
stimulate the angiotensin AT 2 receptor. 
Even if circulating Ang II levels were 
restored to nearly normal (as described 
for ACEIs given alone), generation of 
detrimental metabolites of Ang II (such 
as PAI-stimulating Ang IV) should not 
exceed that under normal conditions. 
 Actions of the RAS mediated by the 
recently described (pro)renin receptor 
(PRR) may provide clues about this appar-
ent paradox. When renin binds to PRR, its 
catalytic activity increases fourfold, and its 
anchoring to the membrane colocalizes it 
with ACE and AT 1 , contributing to highly 
effi  cient generation and activity of Ang II 
( Figure 1 ). Prorenin circulates in tenfold 
greater concentration and binds to PRR 
with greater affi  nity than renin. Binding 
to PRR makes prorenin active by inducing 
a conformational change that exposes its 
angiotensinogen-binding site without 
proteolysis. Th us, prorenin contributes to 
generation of Ang II in the membrane-
bound phase. Moreover, renin or prorenin 
binding to PRR activates intracellular 
signal transduction pathways involved in 
tissue damage, independent of Ang II for-
mation or action (for example, in AT 1 
knockout mice). Activated proteins 
include the mitogen-activated protein 
kinases extracellular signal-regulated 
kinase 1 (ERK1; p44) and ERK2 (p42) in 
mesangial cells and podocytes, 2 p38 and 
heat-shock protein 27 in cardiomyocytes, 3 
and the phosphatidylinositol-3  -kinase 
p85  subunit in cardiomyoblasts and 
human epithelial cells. 4 Downstream 
eff ects include stimulation of profi brotic 
mediators (including transforming growth 
factor-  ), PAI-1, extracellular matrix 
components (fi bronectin and collagen I), 2 
and cell proliferation with inhibition 
of apoptosis. 4 
 Th ese potentially detrimental eff ects 
of PRR activation do not abrogate the 
benefits of monotherapies with ACEIs 
or ARBs in humans. Th e issue is whether 
they may do so when dual blockade of 
RAS leads to profound suppression of Ang 
II generation and action, hence greater 
prorenin and renin secretion. Renin or 
prorenin binding to PRR produces nega-
tive-feedback repression of PRR expres-
sion via nuclear translocation of the 
transcription factor PLZF. 4 Despite this, 
in organs that produce prorenin locally 
(for example, the kidney) or in pathologi-
cal conditions in which tissue prorenin is 
increased (for example, diabetes), prore-
nin may reach the nanomolar concentra-
tions required for its interaction with 
PRR during ACEI – ARB dual blockade, 
thus triggering the Ang II-dependent and 
-independent detrimental actions of 
this receptor. 
 In support of this speculation, the com-
bination of losartan with the direct renin 
inhibitor (DRI) aliskiren reduced pro-
teinuria more than losartan alone (without 
associated harm signals) in subjects with 
diabetic nephropathy in the Aliskiren in 
the Evaluation of Proteinuria in Diabetes 
(AVOID) trial. 5 Th e DRI may have sup-
pressed membrane-bound generation of 
Ang II via inhibition of the catalytic activ-
ity of renin and prorenin, and also dimin-
ished Ang II action by decreasing 
expression of AT 1 . Notably, aliskiren also 
reduces expression of PRR. 6 Th erefore, it 
may also have blunted activation of detri-
mental signal transduction pathways to 
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some extent. Th e ongoing Aliskiren Trial 
in Type 2 Diabetes Using Cardiorenal Dis-
ease Endpoints (ALTITUDE) (cardiorenal 
morbidity and mortality in subjects treated 
with ACEIs or ARBs, given additional 
aliskiren) will provide important informa-
tion on the combinations DRI plus ACEI 
and DRI plus ARB, because it assesses 
clinical outcomes rather than proteinuria, 
a surrogate marker. 7 
 Th eoretically, a DRI plus a PRR blocker 
would constitute the ultimate combination 
for profound blockade of the RAS. How-
ever, information obtained with the puta-
tive blockers of PRR known to date 
(peptides that mimic the handle and hinge 
regions of the prorenin prosegment) is 
highly controversial. Initially, the handle 
peptide was thought to prevent activation 
of inactive prorenin, regardless of binding 
to PRR. Later, inhibition of prorenin bind-
ing to PRR, with consequent inhibition of 
signal transduction and target organ dam-
age, was reported in several, but not in 
other, publications, perhaps depending on 
the dose of peptide, tissue, species, or 
experimental model used (reviewed by 
Reudelhuber 8 ). Th e handle peptide also 
inhibits renin binding to PRR, for which 
there is no clear explanation, as renin lacks 
the prosegment. Finally, it has been 
reported that this peptide paradoxically 
inhibits benefi cial eff ects of aliskiren in 
spontaneously hypertensive rats. When 
given together with aliskiren, it blunts the 
reductions in blood pressure and AT 1 
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 Figure 1  |  Effects of renin and prorenin in the presence of blockers of the renin – angiotensin 
system.  ( a ) The pathways by which the renin – angiotensin system can lead to target organ damage. 
The top arrow points to the classical (e.g., plasma) cascade. The middle arrow shows binding 
of renin (R) and inactive prorenin (iProR) to the (pro)renin receptor (PRR). Prorenin becomes 
enzymatically active (A) by a non-proteolytic conformational change. Generation and action 
of angiotensin II (Ang II) in the membrane-bound compartment is efficient owing to increased 
catalytic activity. The bottom arrow indicates that on binding of R and prorenin to PRR, multiple 
signal transduction pathways are activated (see text). ACE, angiotensin-converting enzyme; Ang I, 
angiotensin I; AT1R, angiotensin type 1 receptor; ERK, extracellular signal-regulated kinase; HSP27, 
heat-shock protein 27; PI3K, phosphatidylinositol-3  -kinase. ( b ) Speculative scenario in which, upon 
virtually complete inhibition of the plasma cascade by combined ACE inhibitors and AT1R blockers 
(ACEI  +  ARB), the reactive rise of R and iProR will activate signal transduction and may (?) overcome 
ACE inhibition and surmount AT1R blockade in the membrane-bound compartment. ( c ) Despite 
producing an even greater reactive rise of R and iProR, aliskiren will prevent membrane-bound 
generation of Ang II, because the enzymatic activities of both R and active prorenin are inhibited. 
In contrast, binding of aliskiren-inhibited R and active prorenin to PRR does not prevent signal 
transduction. ( d ) Theoretical scenario in which membrane-bound generation of Ang II is inhibited 
by aliskiren, whereas signal transduction of PRR is inhibited by a specific, yet-to-be-developed PRR 
blocker (PRRB). 
expression, the enhanced endothelial 
responses to bradykinin, the reduction of 
coronary responses to Ang II, and the 
decrease in cardiomyocyte hypertrophy 
produced by aliskiren alone. 9 Th erefore, 
testing of the eff ect of PRR blockade in 
humans will have to wait for the develop-
ment of specifi c, orally bioavailable com-
pounds that block signal transduction by 
this receptor. Th e search for such com-
pounds has begun, using high-throughput 
screening methodology. 10 
 In summary, the paper by Chan  et al. 1 
contributes to the increasing evidence for 
a lack of benefi t (or even harm) produced 
by dual ACEI – ARB therapy. Th is suggests 
that incomplete blockade of RAS by 
ACEIs  +  ARBs allows the unfavorable 
(Ang II-dependent and -independent) 
actions of PRR to occur in response to 
reactive increases in active prorenin and 
renin. It also suggests that DRIs may 
improve on the ACEI – ARB combination 
(either alone or combined with ACEIs or 
ARBs) by blocking the enzymatic activity 
of reactive renin and prorenin, and by 
decreasing the expression of the AT 1 and 
PRR genes. Finally, it provides impetus for 
the idea that blockade of PRR signal trans-
duction by newly developed compounds 
may constitute the next therapeutic break-
through for profound and beneficial 
blockade of the RAS in human cardiovas-
cular and renal disease. 
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